Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AmerisourceBergen

Johnson & Johnson

McKesson

The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a statement on Monday.

U.S. should review drugmakers' opioid settlement tax breaks - House panel

Amcor Plc

Realty Income Corp

Exxon Mobil

While most of the attention this past week has been focused on the conflict between Ukraine and Russia, the real problem for investors is the mounting inflation pressures that are at the highest levels in over 40 years.

The Bear Market Is Growling: 5 Dividend Aristocrats to Buy Now for Safety and Income

CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that each company has independently determined that there is sufficient participation by states and litigating political subdivisions to proceed with a comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities. The companies have previously disclosed that 46 of 49 eli

Distributors Approve Opioid Settlement Agreement

Chubb

General Electric

GlaxoSmithKline

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Leggett & Platt

Mondelez

Altria

PepsiCo

Philip Morris

With February already underway, it is time for all dividend income investors to look back at the previous month and see how much passive dividend income our portfolios generated.

Dividend Income Update January 2022

Cue Health

SAN DIEGO and DUBLIN, Ohio, Feb. 17, 2022 /PRNewswire/ -- Today Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, and Cardinal Health (NYSE: CAH) announced expanded distribution of Cue's professional use and over-the-counter COVID-19 tests. Cue selected Cardinal Health, which serves nearly 90% of US hospitals and over 60,000 pharmacies, as one of its primary distributors due to a demonstrated expertise in helping commercialize diagnostic technologies.

Cue Health Taps Cardinal Health to Distribute its Pioneering Molecular COVID-19 Tests

Cardinal Health continues its track record of strong revenue growth.

Why Cardinal Health Is A Sound Buy In This Crazy Market

DUBLIN, Ohio, Feb. 10, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) has been recognized by Forbes as one of America's Best Large Employers 2022, a list of more than 500 public and private corporations, hospitals, universities and more, across dozens of industries.    Forbes identified America's Best Employers through an independent survey taken by approximately 60,000 American employees working for U.S. companies that employ more than 1,000 people.

Cardinal Health named one of America's Best Large Employers 2022 by Forbes magazine

DUBLIN, Ohio, Feb. 9, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced it will leverage the Kinaxis® RapidResponse® platform to increase medical product visibility and supply chain agility. Kinaxis will enhance Cardinal Health's medical supply chain through concurrent planning and end-to-end network visibility and transparency while factoring in seasonality and pandemic planning; instantly balance demand and supply while accounting for capacity safeguards; and simulate product supply scenarios in seconds to create best-fit solutions for customers.

Cardinal Health partners with Kinaxis to optimize digital supply chain planning

DUBLIN, Ohio , Feb. 7, 2022 /PRNewswire/ -- Today Cardinal Health published its 2022 Biosimilars Report: The U.S. Journey and Path Ahead, a publication that brings together the latest industry data on biosimilar utilization and payer coverage with survey data from healthcare providers, and views from leading physicians and experts on biosimilars. The report delivers robust data and insights on where biosimilar adoption stands today in the U.S. and what is expected in 2022 and beyond as biosimilars come to market in key disease categories such as diabetes and immunology.

Cardinal Health Predicts 2022 to be Turning Point for Biosimilars in the U.S.

CAH has had a rough go the past few years with the opioid epidemic and coronavirus pandemic impacting their bottom line. Profit margins leave much to be desired and need to improve. Investors can expect a conservative total return CAGR of 14.7% over 5 years.

Cardinal Health: Call The Doctor, Share Buybacks Have Me Swooning

Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.

Cardinal Health (CAH) Q2 Earnings and Revenues Top Estimates

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q2 2022 Results - Earnings Call Transcript

Cardinal (CAH) delivered earnings and revenue surprises of 3.25% and 1.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Beats Q2 Earnings and Revenue Estimates

Cardinal Health CAH has reported Q2 FY22 adjusted EPS of $1.27, down 27% Y/Y, beating the Street estimate of $1.23. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Cardinal Health's Q4 Earnings Hit By Inflationary Impacts, Supply Chain Constraints; Lowers FY22 Outlook

DUBLIN, Ohio, Feb. 3, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2022 revenues of $45.5 billion, an increase of 9% from the second quarter of last year. Second quarter GAAP operating loss was $950 million due to a non-cash, pre-tax goodwill impairment of $1.3 billion related to the Medical segment.

Cardinal Health Reports Second Quarter Fiscal 2022 Results

Last year, Ember outlined one of the more fascinating expansions of recent vintage we've seen in the hardware space. Primarily known for its smart mugs designed to keep their contents hot, the firm took a long, hard look at the cold chain — specifically, the transport of medicine across distances.

Ember expands into cold chain medical shipping with new device, Cardinal Health partnership

Drug distributor Cardinal Health Inc has agreed to pay more than $13 million to resolve allegations that it paid doctors kickbacks to purchase specialty pharmaceutical products from it rather than rivals, the U.S. Justice Department said on Monday.

Cardinal Health to pay $13 million to resolve U.S. kickback case

LOS ANGELES, Jan. 31, 2022 /PRNewswire/ -- Ember Technologies, Inc. (Ember®) and Cardinal Health (NYSE: CAH) today announced a partnership to offer the world's first self-refrigerated, cloud-based shipping box–the Ember Cube. Ember and Cardinal Health will collaborate to deliver a cold chain solution that ensures product integrity and security throughout the supply chain, while significantly reducing shipping waste in the transport of temperature-sensitive medicines.

Ember Technologies and Cardinal Health Partner to Transform the Pharmaceutical Cold Chain

Cardinal Health (CAH) closed at $52.63 in the latest trading session, marking a +0.61% move from the prior day.

Cardinal Health (CAH) Gains But Lags Market: What You Should Know

DUBLIN, Ohio, Jan. 27, 2022 /PRNewswire/ -- Cardinal Health again has earned the perfect score of 100% on the Human Rights Campaign Foundation's Corporate Equality Index (CEI), a national benchmarking tool to measure corporate policies and practices related to LGBTQ+ (lesbian, gay, bisexual, transgender, queer and other) workplace equity. Organizations that have earned a 100% rating on the CEI have satisfied all criteria for the year and are recognized as a "Best Place to Work for LGBTQ+ Equality.

Cardinal Health earns perfect score on Human Rights Campaign Foundation's Corporate Equality Index for the 14th consecutive year

Alibaba

SPDR Gold Trust

Henkel AG & Co KGaA

PayPal

Tencent Holdings Limited

Walgreens

Without any doubt, the US stock market remains extremely overvalued and we should therefore move with extreme caution. But we can still try to identify bargains in the market and I present six equities and a precious metal as picks for 2022.

Good, Better, Great: 7 Assets To Buy In 2022

Camping World Hlds

Enbridge

And if you hang onto these investments, that income could even rise over time.

Want to Make an Extra $4,000 in 2022? Invest $78,000 in These 3 Dividend Stocks

Cardinal Health looks like a great long-term value investment current trading at 10.0x forward P/E. The company does a good job returning cash to shareholders through share repurchases of 2.1% annually in addition to the current 3.76% dividend yield.

Cardinal Health: Attractive Long-Term Investment At 10.0x Forward P/E

Earnings are not as healthy as they could be.

Bear of the Day: Cardinal Health (CAH)

Cardinal Health, Inc. (CAH) Management Presents at 40th JPMorgan Annual Healthcare Conference (Transcript)

News for Cardinal Health Stock (CAH)